Back to results

Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food

Primary Purpose

Trypanosomiasis, African

Status

Terminated

Phase

Phase 1

Locations

France

Study Type

Interventional

Intervention

Tablets Fexinidazole

Placebo

About this trial

This is an interventional treatment trial for Trypanosomiasis, African

Eligibility Criteria

18 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

Male healthy volunteers 18 to 45 years of age,
All subjects to be of sub-Saharan African origins with both parents of sub-Saharan African origins too,
Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m)2 from 18 to 28 kg/m2 inclusive at screening,
Able to communicate well with the Investigator and research staff and to comply with the requirements of the entire study,
Provision of written informed consent to participate as shown by a signature on the volunteer consent form,
Light smokers (less than 10 cigarettes per day) or subjects who are non-smokers. No smoking (or use of smoking substitute e.g. nicotine patch) is permitted from screening throughout the study,
Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator. These will be measured after resting for 5 min,
Registered with the French Social Security in agreement with the French law on biomedical experimentation.

Exclusion Criteria:

Who on direct questioning and physical examination have evidence of any clinically significant acute or chronic disease, including known or suspected HIV, HBV or HCV infection,
With any clinically significant abnormality following review of pre-study laboratory tests(ASAT, ALAT and alkaline phosphatase (ALP) must be within normal ranges), vital signs, full physical examination and ECG,
Who are within the exclusion period defined in the National Register for Healthy Volunteers of the French Ministry of Health,
Who forfeit their freedom by administrative or legal award or who were under guardianship,
Unwilling to give their informed consent,
Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or anti-HIV 1/2 or anti-HCV antibodies
Who have a history of allergy, intolerance or photosensitivity to any drug,
Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to any drug,
Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per week, one unit = 8 g or about 10 mL of pure alcohol),
Who drink more than 8 cups daily of beverage containing caffeine,
Who have a positive laboratory test for urine drug screening (opiates, cocaine,amphetamine, cannabis, benzodiazepines),
Who have undergone surgery or have donated blood within 12 weeks prior to the start of the study,
Who have taken any prescribed or over the counter drug (including antacid drug), with the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first dose administration,
Who have any clinical condition or prior therapy which, in the opinion of the Investigator, made the subject unsuitable for the study,
Who participated to any clinical trial with an investigational drug in the past 3 months preceding study entry.

Sites / Locations

SGS Life Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Fexinidazole

Placebo fexinidazole

Arm Description

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

NCT ID

NCT01483170

First Posted

November 29, 2011

Last Updated

March 29, 2017

Sponsor

Drugs for Neglected Diseases

1. Study Identification

Unique Protocol Identification Number

NCT01483170

Brief Title

Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food

Official Title

Double-blind, Placebo Controlled, Randomized Multiple Ascending Dose Study in Fed Conditions for Ten Days Dosing Regimen With a Loading Dose to Evaluate the Safety, the Tolerability and the Pharmacokinetics of Oral Fexinidazole in 36 Healthy Male Sub-Saharan Volunteers.

Study Type

Interventional

2. Study Status

Record Verification Date

March 2017

Overall Recruitment Status

Terminated

Why Stopped

poor tolerability at highest dose

Study Start Date

September 2011 (undefined)

Primary Completion Date

December 2011 (Actual)

Study Completion Date

February 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Drugs for Neglected Diseases

4. Oversight

5. Study Description

Brief Summary

This trial will study the tolerability and pharmacokinetic of fexinidazole using two different dosage regimen of repeated administrations. The drug is administered to human healthy volunteers of sub-saharan origin together with food, once a day during 10 days, with a loading dose during 4 days.

Detailed Description

Objectives: Primary Objectives: To assess safety and tolerability of two different fexinidazole dosing regimen, for 10 days repeated administration under fed conditions in healthy male sub-Saharan volunteers. Secondary objectives: To validate the exposure to fexinidazole, M1 and M2 after different dosing regimens in fed conditions for 10 days in order to evaluate the more appropriate administration regimen for the pivotal phase II/III study. Methodology/Study Design: Two dose regimens consisting of repeated oral ascending dose (OAD) dosing in fed condition with two different ascending loading doses for 4 days followed by the same dose for 6 days will be evaluated. The study will be conducted in double-blind conditions for both the clinical and bioanalytical parts. For each dosing regimen, subjects will reside at the clinical unit from the evening of Day -2 to the afternoon of Day 17 including an 8 days safety follow up (168 h post last dose).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Trypanosomiasis, African

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

30 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Fexinidazole

Arm Type

Experimental

Arm Title

Placebo fexinidazole

Arm Type

Placebo Comparator

Intervention Type

Drug

Intervention Name(s)

Tablets Fexinidazole

Intervention Description

Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.

Intervention Type

Drug

Intervention Name(s)

Placebo

Intervention Description

Placebo fexinidazole

10. Eligibility

Sex

Male

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

45 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Male healthy volunteers 18 to 45 years of age, All subjects to be of sub-Saharan African origins with both parents of sub-Saharan African origins too, Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m)2 from 18 to 28 kg/m2 inclusive at screening, Able to communicate well with the Investigator and research staff and to comply with the requirements of the entire study, Provision of written informed consent to participate as shown by a signature on the volunteer consent form, Light smokers (less than 10 cigarettes per day) or subjects who are non-smokers. No smoking (or use of smoking substitute e.g. nicotine patch) is permitted from screening throughout the study, Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator. These will be measured after resting for 5 min, Registered with the French Social Security in agreement with the French law on biomedical experimentation. Exclusion Criteria: Who on direct questioning and physical examination have evidence of any clinically significant acute or chronic disease, including known or suspected HIV, HBV or HCV infection, With any clinically significant abnormality following review of pre-study laboratory tests(ASAT, ALAT and alkaline phosphatase (ALP) must be within normal ranges), vital signs, full physical examination and ECG, Who are within the exclusion period defined in the National Register for Healthy Volunteers of the French Ministry of Health, Who forfeit their freedom by administrative or legal award or who were under guardianship, Unwilling to give their informed consent, Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or anti-HIV 1/2 or anti-HCV antibodies Who have a history of allergy, intolerance or photosensitivity to any drug, Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to any drug, Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per week, one unit = 8 g or about 10 mL of pure alcohol), Who drink more than 8 cups daily of beverage containing caffeine, Who have a positive laboratory test for urine drug screening (opiates, cocaine,amphetamine, cannabis, benzodiazepines), Who have undergone surgery or have donated blood within 12 weeks prior to the start of the study, Who have taken any prescribed or over the counter drug (including antacid drug), with the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first dose administration, Who have any clinical condition or prior therapy which, in the opinion of the Investigator, made the subject unsuitable for the study, Who participated to any clinical trial with an investigational drug in the past 3 months preceding study entry.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Lionel Hovsepian, MD

Organizational Affiliation

SGS Aster

Official's Role

Principal Investigator

Facility Information:

Facility Name

SGS Life Sciences

City

Paris

ZIP/Postal Code

75015

Country

France

12. IPD Sharing Statement

Plan to Share IPD

Undecided

Links:

URL

http://www.dndi.org

Description

Sponsor website

URL

http://www.dndi.org/wp-content/uploads/2009/06/ClinicalPK_Tarral_FexinidazoleHAT_2014.pdf

Description

Publication combining results of NCT00982904 + NCT01340157

Learn more about this trial

Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food

We'll reach out to this number within 24 hrs